Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shazia K Nakhoda

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Pharmaceutical Medicine|March 12, 2020
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment StrategiesShazia K Nakhoda, Anthony J Olszanski
Clinical Nuclear Medicine|March 4, 2021
COVID-19 Vaccine-Related Local FDG UptakeMohan Doss, Shazia K Nakhoda, Yi Li, et al.
Cancer Medicine|November 27, 2025
"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous TransplantationZachary A K Frosch, Clark Meshack, Caitlin Meeker, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Pharmaceutical Medicine|March 12, 2020
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment StrategiesShazia K Nakhoda, Anthony J Olszanski
Clinical Nuclear Medicine|March 4, 2021
COVID-19 Vaccine-Related Local FDG UptakeMohan Doss, Shazia K Nakhoda, Yi Li, et al.
Cancer Medicine|November 27, 2025
"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous TransplantationZachary A K Frosch, Clark Meshack, Caitlin Meeker, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Pageof 1